10-Year Study: Ozanimod Generally Safe for MS

Credibility

Interest

Key Takeaway

Ten years of daily ozanimod treatment showed a generally well-tolerated safety profile with few serious side effects for people with relapsing MS or ulcerative colitis.

What They Found

Researchers combined data from many clinical trials and followed 3,652 people for a total of 16,144 patient-years to see how safe ozanimod is over a long time. The most common side effects were mild things like a sore throat or cold (nasopharyngitis), headaches, and COVID-19, which are similar to what many people might feel with common infections. Serious problems that made people stop the drug were rare, about 1.4 people for every 100 years of treatment; other serious concerns like major infections, shingles, new cancers, slow heart rate, or eye swelling (macular edema) were also uncommon. The drug did not cause serious liver injury in these studies, and very low white blood cell counts (absolute lymphocyte count under 200 cells/µL) were not linked in time to serious or unusual infections. Overall, the long-term data support that daily ozanimod is usually safe and the serious risks are uncommon when people are monitored during treatment.

Who Should Care and Why

People with relapsing MS should care because ozanimod is a treatment option that can be taken by mouth and appears to be safe over many years for most patients, which matters when choosing long-term therapy. Caregivers will want to know that most side effects are mild and that serious problems are uncommon, so daily routines and support needs may be fairly stable for many patients. Neurologists and MS nurses should note these results when discussing long-term treatment plans and monitoring schedules with patients, similar to checking oil and tires on a car regularly to prevent bigger problems. People with other health concerns (like heart or eye issues) should discuss individual risk with their doctor, because even rare side effects (like slow heart rate or eye swelling) may matter depending on a person’s history. Overall, this study helps patients and caregivers weigh the benefits of a convenient oral medicine against a low chance of serious side effects, using regular checkups to keep things safe.

Important Considerations

This combined analysis pools many trials but was not a single new experiment, so differences between study groups or monitoring practices could affect results. Very rare problems might not show up even in this large group, so low risk does not mean zero risk — continued monitoring is important. Individual risks can vary (for example, underlying heart, eye, or infection history), so patients should talk with their clinician about how these results apply to their personal health.

Categories:

Treatment Updates Clinical Trials MS Progression

Article Topics:

ozanimodrelapsing multiple sclerosisulcerative colitis

Whether you’ve recently been diagnosed with Multiple Sclerosis (MS) or are seeking to broaden your understanding of this complex, neurodegenerative disease, navigating the latest research can feel overwhelming. Studies published in respected medical journals like Inflammatory bowel diseases often range from early-stage, exploratory work to advanced clinical trials. These evidence-based findings help shape new disease-modifying therapies, guide symptom management techniques, and deepen our knowledge of MS progression.

However, not all research is created equal. Some clinical research studies may have smaller sample sizes, evolving methodologies, or limitations that warrant careful interpretation. For a more comprehensive, accurate understanding, we recommend reviewing the original source material—accessible via the More Details section above—and consulting with healthcare professionals who specialize in MS care.

By presenting a wide range of MS-focused studies—spanning cutting-edge treatments, emerging therapies, and established best practices—we aim to empower patients, caregivers, and clinicians to stay informed and make well-informed decisions when managing Multiple Sclerosis.

Back to News